Clear cell renal cell carcinoma (ccRCC) is the most frequent histological kidney cancer
subtype. Over the last decade, significant progress has been made in identifying the genetic …

Abstract The Cancer Genome Atlas (TCGA) characterized the somatic genetic and genomic
alterations in renal cell carcinoma (RCC) encompassing the major RCC histological …

Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …

PD-1 blockade has transformed the management of advanced clear cell renal cell
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …

Metastatic cancer is a major cause of death and is associated with poor treatment efficacy. A
better understanding of the characteristics of late-stage cancer is required to help adapt …

DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic
response. We systematically analyzed somatic alterations to provide a comprehensive view …

Advances in omics technologies—such as genomics, transcriptomics, proteomics and
metabolomics—have begun to enable personalized medicine at an extraordinarily detailed …

Immune checkpoint inhibitors targeting the programmed cell death 1 receptor (PD-1)
improve survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). To …

Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …

Treatments that target immune checkpoints, such as the one mediated by programmed cell
death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human …